The Future of Psychedelic Assisted Therapy
Date: Oct 23, 2020
October 23, 2020- 7:00PM US Pacific Time
Psychedelic assisted psychotherapy is on track to be the next breakthrough in mental health care. The last decade has seen a renaissance in the field of psychedelic science—moving it from the fringes of the scientific world to the mainstream with startling speed, legitimizing the medical potential of psychedelic drugs. Within the next decade, we are likely to have multiple psychedelic-assisted therapies approved in the US, Europe, and in many countries around the world for the treatment of various mental health conditions. As psychedelic therapy treatment success stories continue to emerge, and new scientific evidence from clinical trials show positive results, more patients will be asking for these treatments. In the coming years, we could see psychedelic therapy used in new treatment centers, psychiatric hospitals, privately owned clinics, as well as with independent practitioners.
Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS) has been a relentless advocate for developing legal contexts for the beneficial uses of psychedelics for decades and continues to be at the forefront of psychedelic-assisted treatment of PTSD, depression, and mental illness.
Join licensed psychotherapist and CIIS professor Gisele Fernandes for a fascinating conversation with Rick on the future of psychedelic assisted psychotherapy. Diving into his vast knowledge of the science of psychedelics, Rick discusses how drugs like LSD, psilocybin and MDMA affect your brain. He shares how, when paired with psychotherapy, psychedelics could change the way we treat PTSD, depression, substance abuse, and more.
Discover what the future holds for psychedelic assisted psychotherapy and the treatment of mental health.